GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (OTCPK:ROQAF) » Definitions » Interest Coverage

ROQAF (Roquefort Therapeutics) Interest Coverage : 0 (At Loss) (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Roquefort Therapeutics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Roquefort Therapeutics's Operating Income for the six months ended in Dec. 2024 was $-0.56 Mil. Roquefort Therapeutics's Interest Expense for the six months ended in Dec. 2024 was $-0.04 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Roquefort Therapeutics's Interest Coverage or its related term are showing as below:


ROQAF's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 117.6
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Roquefort Therapeutics Interest Coverage Historical Data

The historical data trend for Roquefort Therapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Roquefort Therapeutics Interest Coverage Chart

Roquefort Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Interest Coverage
No Debt No Debt No Debt -

Roquefort Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Interest Coverage Get a 7-Day Free Trial No Debt No Debt No Debt - -

Competitive Comparison of Roquefort Therapeutics's Interest Coverage

For the Biotechnology subindustry, Roquefort Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Roquefort Therapeutics's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roquefort Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Roquefort Therapeutics's Interest Coverage falls into.


;
;

Roquefort Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Roquefort Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2024 is calculated as

Here, for the fiscal year that ended in Dec. 2024, Roquefort Therapeutics's Interest Expense was $-0.06 Mil. Its Operating Income was $-1.41 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Roquefort Therapeutics did not have earnings to cover the interest expense.

Roquefort Therapeutics's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Here, for the six months ended in Dec. 2024, Roquefort Therapeutics's Interest Expense was $-0.04 Mil. Its Operating Income was $-0.56 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Roquefort Therapeutics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Roquefort Therapeutics  (OTCPK:ROQAF) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Roquefort Therapeutics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Roquefort Therapeutics Business Description

Traded in Other Exchanges
Address
85 Great Portland Street, First Floor, London, GBR, W1W 7LT
Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses. Its product portfolio consists of MDK Antibody, MDK Oligo, MDK mRNA, STAT-6 siRNA, and MK Cell. The principal activity of the Company is to develop pre-clinical next-generation medicines focused on hard-to-treat cancers.

Roquefort Therapeutics Headlines